After years of animal testing, researchers at Penn State now have developed a therapy aimed at treating some of the most resistant cancers without damaging any healthy cells.
Called Ceramide NanoLiposome, this treatment has just started the early stages of human testing.
James and Bernadette Adair are both scientists and researchers at Penn State University. Married 27 years, they’ve loved doing everything together, except battling cancer. Bernie was diagnosed with breast cancer in 2007.
“We were still dealing with me when Jim was diagnosed,” said Bernie.
Doctors found Jim’s colon cancer in 2008.
Both were treated and are now cancer-free.
Ironically, even before his or his wife’s diagnosis, James had been working to develop a new treatment for cancer through nanotechnology: manipulating cells at the molecular level. It’s called Ceramide NanoLiposome.
“It was at that time an experimental chemotherapeutic that had unique properties,” said James.
The Ceramide NanoLiposome is infused into the body. Because of the tiny size and structure, the nanoparticles travel easily through the body and can slip into tumors, killing the deadly cells and leaving healthy cells intact.
Jim formed a separate company, Keystone Nano, to continue the research, especially for cancers that have few other effective treatments, like liver cancer.
“Kill the cancer, do no harm to the patient,” said James. “To someone like me who is a cancer survivor, that’s awesome.”
While this development is a decade too late for Jim and Bernie Adair, it may help countless cancer patients live full lives down the road.
Jeff Davidson, the CEO of Keystone Nano, said, “The animal models have shown great efficacy against that cancer.”
The FDA has approved the therapy for phase one clinical trials.
Those are happening at three US institutions: the Greenebaum Cancer Center of the University of Maryland, the Medical University of South Carolina, and the University of Virginia Cancer Center.
Researchers are testing the dosing levels on cancer patients for whom other therapies are not working.
TOPIC: NANOTECHNOLOGY TO TREAT CANCER?
r, breast cancer, lung cancer, prostate cancer, colon cancer, and lymphoma. Symptoms vary depending on the type of cancer a person has. Common causes of cancer include things such as smoking and tobacco products, poor diet and limited physical activity, sun and other types of radiation, and certain viruses or other infections. Some known and possible environmental causes, including exposure to different types of chemicals and radiation may include acrylamide, alcohol, arsenic, asbestos, benzene, cell phones and towers, cosmetics, diesel exhaust, formaldehyde, lead, microwaves and radio waves, power lines, radon, talcum powder, tetrachloroethylene, and X-rays or gamma rays.
TREATMENT: The most common types of cancer treatment may include surgery, radiation, and/or chemotherapy. A person may also receive targeted therapy or immunotherapy, or other procedures including stem cell transplant, hyperthermia, photodynamic therapy, blood transfusions and donations, or lasers in cancer treatment. Treatment options may vary depending on a person’s medical history, stage in which they are diagnosed and health care coverage and costs. There are also newer forms of treatment options and information on clinical trials, complementary and alternative therapies as well. Treatment may come with a variety of side effects separate from the cancer itself.
NEW TECHNOLOGY: A new treatment is now in early phases of testing; Ceramide NanoLiposomes are targeted to treat more resistant cancers without damaging any healthy cells in the process. Made up of lipids, most of which occur naturally in the body, they are stable in the blood and circulate well. These NanoLiposomes easily enter tumor cells to deliver ingredients that destroy cancer cells. You can load both hydrophilic and hydrophobic compounds into these NanoLiposomes, and actives are stored within its core to prevent degradation during circulation throughout the body. They are stable during circulation and release payloads intracellularly following membrane fusion. They can be targeted through size and surface charge, or a wide range of targeting materials can be attached to the surface.Discover More